Novo Nordisk has announced the failure of its Alzheimer’s trials, where an older oral version of their semaglutide drug did not succeed in slowing the disease’s progression. This outcome has impacted the market standing against competitors like Eli Lilly, affecting the company’s shares and strategic direction.
